BioSpace News Archive

Under the terms of the exclusive distributor and license agreement, Innovus will receive a payment at signing, as well as milestone payments based on Acerus achieving certain sales targets.

Under the agreement, Innovus Pharma will receive an up-front license payment and is eligible to receive up to CAD$1.65 million dollars in sales milestone payments plus minimum order quantities at an agreed-upon transfer price.

Total revenue for the full year of 2017 is expected to be approximately $18 million, up 51% from 2017.

Merck today announced that the FDA has accepted for review two New Drug Applications (NDAs) for doravirine, the company’s investigational non-nucleoside reverse transcriptase inhibitor (NNRTI) for the treatment of HIV-1 infection in adults.

During the quarter ending December 31, 2017, the Company sold two Senhance Systems for total revenue of approximately $3.3 million.

The Company’s common stock will begin trading on a split-adjusted basis when the markets open on January 22, 2018 under the existing trading symbol “OGEN”.

The effective date of the name change, approved by shareholders in December 2017, is expected to be January 10, 2018.

The company announced that preliminary unaudited fourth quarter worldwide revenue is expected to be in the range of $97.4 to $97.9M.

IDEXX Labs today announced that the IDEXX Catalyst SDMA Test will be commercially available to all North American customers on January 16, 2018.

Can-Fite announced it has signed a distribution agreement with Gebro Holding GmBH to distribute Can-Fite’s lead drug candidate, Piclidenoson (CF101), for the treatment of rheumatoid arthritis and psoriasis in 3 European countries including Spain, Switzerland and Austria, upon receipt of regulatory approvals.